Samba BioLogics Selected for MassBio’s Biotech Accelerator, MassBioDrive in Spring 2023 Cohort of Startups
The latest cohort of MassBioDrive, a key initiative of MassBio’s innovation programming designed to support entrepreneurs and…
Samba BioLogics, Inc. Awarded NIH SBIR/STTR Program Grant
VasaPlex-based biologics for treatment of reperfusion injury after myocardial infarction.
Samba BioLogics Selected for NIH-sponsored DRIVEN Program
Samba BioLogics, Inc. was selected for the NIH-sponsored DRIVEN Program to commercialize our biologics + IP (incubator at Celdara…
Spees’ New NIH Grant to Expand Study of Novel Post-Heart Attack Therapy
A heart attack continues to harm cardiac muscle even after the immediate problem – a blocked artery – is fixed, but University of…
VasaPlex Featured on WCAX-TV
On August 10, 2016, Jeffrey Spees, PH.D., associate professor in the Division of Cardiovascular Medicine, was featured in a story…
SPARK VT Initiative Supports UVM Researchers on the Path to Commercialization
SPARK facilitates the discovery-to-commercialization process for those researchers who, working through UVM Innovations, are have…
Priming “Cocktail” Shows Promise as Cardiac Stem Cell Grafting Tool
New research by University of Vermont Associate Professor of Medicine Jeffrey Spees, Ph.D., and colleagues has identified a new…
Jeff Spees Guest Appearance Vermont Public Radio (NPR) to Discuss Changes to US Stem Cell Policy
We talk with Jeff Spees, the Director of UVM’s Stem Cell Core facility to learn more about UVM’s research. And we also find out…